Phibro Animal Health (PAHC) Q1 2025 earnings summary

Executive summary

• Net sales rose 13% year-over-year to $260.4 million for Q1 FY25, driven by strong growth in Animal Health, Mineral Nutrition, and Performance Products segments.

• Animal Health led with 14% sales growth, including 22% growth in vaccines and 15% in MFAs and other products; net income turned positive to $7.0 million from a prior year loss.

• Adjusted EBITDA increased 64% to $30.7 million, and adjusted net income rose to $14.1 million.

• Successfully closed the $350 million acquisition of Zoetis's medicated feed additive (MFA) business, with integration underway.

• Discontinued the atopic dermatitis (Dermacare) project after failing to meet targets; focus remains on pipeline and strategic growth.

Financial highlights

• Q1 consolidated net sales: $260.4 million (+13%); gross profit up 23% to $83.5 million, gross margin improved to 32.1%.

• Adjusted EBITDA: $30.7 million (+64%); adjusted net income: $14.1 million (+155%); adjusted diluted EPS: $0.35 (+154%).

• Animal Health Adjusted EBITDA reached $40.4 million (+42%); Mineral Nutrition $3.8 million (+31%); Performance Products $2.3 million (+62%).

• Cash and equivalents plus short-term investments totaled $90 million at quarter end; free cash flow (TTM) was $41 million.

• Quarterly dividend of $0.12 per share ($4.9 million total) paid.

Outlook and guidance

• FY25 standalone guidance: net sales of $1.05–$1.1 billion (3–8% growth), adjusted EBITDA of $124–$132 million (11–19% growth), adjusted net income of $55–$60 million (14–24% growth), adjusted EPS $1.34–$1.48.

• Guidance excludes Zoetis MFA acquisition; preliminary Zoetis estimates for FY25 (eight months): ~$200 million revenue, ~20% EBITDA margin, ~$0.25 adjusted EPS impact.

• Management expects continued growth in animal health, supported by global population trends and productivity needs.

• Liquidity expected to be sufficient for at least the next twelve months, supported by cash, operations, and credit facilities.

• Guidance includes early benefits and one-time costs from the Phibro Forward income growth initiative.